Helped by growth in the biosimilar and generics segment, biotechnology company Biocon posted topline and bottom-line growth of 21.6% and 72% year-on-year in the first quarter of 2022-23. However, higher cost pressures impacted operating profit margin, which shrank 343 basis points year-on-year. The acquisition of Viatris and the vaccine partnership with Serum Institute have helped the company establish itself as an integrated global